LEHI, UTAH, UNITED STATES, October 27, 2022 – Lumea is pleased to announce the launch of its gastrointestinal (GI) digital pathology platform with Granite Peaks. Granite Peaks is the first…
Read More
Lumea and P4 Diagnostix partnership press release LEHI, UT, October 13, 2022—Lumea Inc, a global leader in integrated digital pathology solutions, is pleased to announce a strategic partnership with P4…
Lumea is pleased to announce a new product line: Lumea+ Digital Pathology. Lumea+ allows labs and pathologists to enhance their existing LIS with proprietary consumables and leading-edge technology that optimizes…
AZoRobotics recently featured the new Lumea and Tempus digital pathology and artificial intelligence collaboration. More advancements are happening between pathology and artificial intelligence every year. This one is particularly exciting because…
Lumea, a leader in digital pathology solutions, has chosen Tempus, a leader in artificial intelligence and precision medicine, to create AI-enabled solutions LEHI, UTAH, UNITED STATES, August 4, 2022 /EINPresswire.com/…
An ancillary or molecular test is a medical test for a patient that is not a part of the original study design. There are a wide variety of ancillary tests…
Recent Comments